Isomorphic Labs
Alphabet-spun-out AI drug discovery company applying AlphaFold and the Drug Design Engine to therapeutic design
Biotech
📍 London, UK
Founded 2021
Current Valuation
$12B
as of 2026-Q2
DECACORN
Isomorphic Labs is an Alphabet-owned AI drug discovery company spun out of DeepMind in 2021, led by DeepMind founder and CEO Demis Hassabis. Builds on AlphaFold (the protein-structure prediction system that won Hassabis the 2024 Nobel Prize in Chemistry) and the 2026 Drug Design Engine, which extends AlphaFold 3 to predict small-molecule binding affinities and discover new binding pockets directly from amino-acid sequences. Has $3B+ in pharma collaboration deals with Novartis and Eli Lilly (signed January 2024). Raised $600M in March 2025 (its first external round) led by Thrive Capital, followed by a $2.1B follow-on in May 2026 led by Thrive with participation from new investors MGX, Temasek, and CapitalG. Headquartered in London with a second office in Lausanne, Switzerland.
Company Profile
Growth
Pre-revenue (drug pipeline still preclinical)
Last Round
Series B — $2.1B (May 2026) · Lead: Thrive Capital
IPO Status
no imminent plans
Founders & Key People
Demis Hassabis
Investors
Thrive Capital · GV (Google Ventures) · Alphabet · CapitalG · MGX · Temasek
Products
- AlphaFold 3 (with Google DeepMind)
- Isomorphic Drug Design Engine
- Internal therapeutic pipeline across oncology, immunology, and rare diseases
Competitors
Recursion Pharmaceuticals · Insitro · Atomic AI · Xaira Therapeutics · Latent Labs · Variational AI
AIBiotechDrug DiscoveryDeepMind SpinoffAlphabetDecacorn
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2026-Q2. Refreshed quarterly.